RITUXIMAB (MABTHERA, RITUXAN)

Course overview

Rituximab is U.S. FDA-approved to treat chronic lymphoid leukemia (CLL), in combination with fludarabine and cyclophosphamide; microscopic polyarteritis nodosa and Wegener granulomatosis, in combination with glucocorticoids; CD20-positive B-cell non-Hodgkin lymphoma (NHL); and moderate/severe rheumatoid arthritis (RA) with prior inadequate response to ≥ 1 tumor necrosis factor (TNF) antagonist, in combination with methotrexate. This continuing education module is designed to give the reader/learner an increased understanding of rituximab. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.